A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells

Tissue Antigens. 2005 Feb;65(2):156-62. doi: 10.1111/j.1399-0039.2005.00365.x.


A panel of autologous cytolytic T lymphocyte (CTL) clones have been isolated from blood lymphocytes of a melanoma patient after in vitro stimulation with autologous tumor cells. We previously reported the molecular definition of three distinct antigens recognized by some of these CTL clones. We describe here, the identification of a fourth antigenic peptide expressed by this melanoma line and recognized by a CTL clone restricted by HLA-B*3503. The antigenic peptide, which is nine-amino acid long, has the sequence LPHSSSHWL and is derived from melanocyte differentiation antigen gp100. As HLA-B35 is one of the most frequent HLA-B alleles, being present in 20% of the Caucasian individuals, this peptide may be a good target for peptide-based immunotherapy of melanoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • COS Cells
  • Chlorocebus aethiops
  • Cytotoxicity, Immunologic
  • HLA-B35 Antigen / genetics
  • HLA-B35 Antigen / immunology*
  • Humans
  • Melanocytes / immunology
  • Melanocytes / metabolism
  • Melanoma / genetics
  • Melanoma / immunology*
  • Membrane Glycoproteins / immunology*
  • Molecular Sequence Data
  • Neoplasm Proteins / immunology*
  • Peptide Fragments / chemistry
  • Peptide Fragments / immunology*
  • Skin Neoplasms / genetics
  • Skin Neoplasms / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Tumor Cells, Cultured
  • gp100 Melanoma Antigen


  • HLA-B35 Antigen
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • PMEL protein, human
  • Peptide Fragments
  • gp100 Melanoma Antigen